Form 8-K - Current report:
SEC Accession No. 0001682852-24-000035
Filing Date
2024-07-23
Accepted
2024-07-23 07:05:39
Documents
15
Period of Report
2024-07-19
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K mrna-20240719.htm   iXBRL 8-K 33632
2 EX-99.1 exhibit991-07232024.htm EX-99.1 14657
6 image_0a.jpg GRAPHIC 116
  Complete submission text file 0001682852-24-000035.txt   178979

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT mrna-20240719.xsd EX-101.SCH 1907
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT mrna-20240719_lab.xml EX-101.LAB 21629
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT mrna-20240719_pre.xml EX-101.PRE 12512
17 EXTRACTED XBRL INSTANCE DOCUMENT mrna-20240719_htm.xml XML 2706
Mailing Address 325 BINNEY STREET CAMBRIDGE MA 02142
Business Address 325 BINNEY STREET CAMBRIDGE MA 02142 6177146500
Moderna, Inc. (Filer) CIK: 0001682852 (see all company filings)

EIN.: 813467528 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38753 | Film No.: 241132905
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)